$NRXP
NRX Pharmaceuticals, Inc.

2022 Q3 Form 10-Q Financial Statement

#000155837022013673 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.012M $6.642M $10.22M
YoY Change -63.74% -46.68% 386.44%
% of Gross Profit
Research & Development $4.129M $2.958M $5.483M
YoY Change -34.21% -36.51% 88.48%
% of Gross Profit
Depreciation & Amortization $1.000K $1.000K $1.000K
YoY Change 56.25% 3.09%
% of Gross Profit
Operating Expenses $9.141M $9.600M $15.71M
YoY Change -54.52% -43.92% -38.66%
Operating Profit -$9.141M -$9.600M -$15.71M
YoY Change -54.52% -43.92% -38.66%
Interest Expense $58.00K $139.0K $3.000K
YoY Change 980.48% 2680.0% -40.0%
% of Operating Profit
Other Income/Expense, Net $58.00K $2.618M $2.257M
YoY Change -108.61% -84.6% 1845.69%
Pretax Income -$9.083M -$6.982M -$13.45M
YoY Change -56.28% -56.38% 1404.73%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$9.083M -$6.982M -$13.45M
YoY Change -56.28% 5816.95% -47.24%
Net Earnings / Revenue
Basic Earnings Per Share -$0.14 -$0.11 -$0.21
Diluted Earnings Per Share -$0.14 -$0.11 -$0.20
COMMON SHARES
Basic Shares Outstanding 67.64M 65.73M 63.67M
Diluted Shares Outstanding 66.45M 65.73M 63.67M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.25M $24.55M $40.20M
YoY Change -53.07% 83.38% 17479030.43%
Cash & Equivalents $18.25M $24.55M $40.20M
Short-Term Investments
Other Short-Term Assets $6.552M $7.866M $3.382M
YoY Change 3.17% 52.81% 5584.99%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $24.80M $32.41M $43.58M
YoY Change -45.17% 74.89% 72875.69%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.00K $19.00K $17.00K
YoY Change 44.46% 49.25%
Total Long-Term Assets $23.00K $19.00K $17.00K
YoY Change 44.46% 49.25% -99.72%
TOTAL ASSETS
Total Short-Term Assets $24.80M $32.41M $43.58M
Total Long-Term Assets $23.00K $19.00K $17.00K
Total Assets $24.82M $32.43M $43.60M
YoY Change -45.14% 74.87% 623.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.168M $3.078M $4.311M
YoY Change -61.0% -50.9% 569.73%
Accrued Expenses $5.067M $3.326M $4.001M
YoY Change 153.86% 120.8%
Deferred Revenue $56.00K $19.00K $135.0K
YoY Change -92.78% -96.31%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $520.0K
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $8.042M $7.081M $11.91M
YoY Change -77.84% -80.04% 1750.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.042M $7.081M $11.91M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $8.042M $7.081M $11.91M
YoY Change -77.84% -80.32% 147.77%
SHAREHOLDERS EQUITY
Retained Earnings -$212.8M -$203.7M -$196.7M
YoY Change 39.56% 54.68% 12088.57%
Common Stock $68.00K $67.00K $67.00K
YoY Change 24.06% 37.85% 2392.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.78M $25.35M $31.69M
YoY Change
Total Liabilities & Shareholders Equity $24.82M $32.43M $43.60M
YoY Change -45.14% 74.87% 623.34%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$9.083M -$6.982M -$13.45M
YoY Change -56.28% 5816.95% -47.24%
Depreciation, Depletion And Amortization $1.000K $1.000K $1.000K
YoY Change 56.25% 3.09%
Cash From Operating Activities -$6.266M -$14.79M -$10.38M
YoY Change -47.85% 29.82% 244.28%
INVESTING ACTIVITIES
Capital Expenditures -$5.000K -$3.000K -$3.000K
YoY Change 30.55% 7.91%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$5.000K -$3.000K -$3.000K
YoY Change 30.55% 7.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -28.00K -860.0K 22.98M
YoY Change -100.07% -107.47% 59.28%
NET CHANGE
Cash From Operating Activities -6.266M -14.79M -10.38M
Cash From Investing Activities -5.000K -3.000K -3.000K
Cash From Financing Activities -28.00K -860.0K 22.98M
Net Change In Cash -6.299M -15.65M 12.60M
YoY Change -124.7% -13615.8% 10.38%
FREE CASH FLOW
Cash From Operating Activities -$6.266M -$14.79M -$10.38M
Capital Expenditures -$5.000K -$3.000K -$3.000K
Free Cash Flow -$6.261M -$14.79M -$10.38M
YoY Change -47.87% 29.83% 244.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001719406
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Registrant Name
EntityRegistrantName
NRX Pharmaceuticals, Inc.
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66641314
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58510550
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-118000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-281428000
nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
23000000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38302
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2844431
dei Entity Address Address Line1
EntityAddressAddressLine1
1201 Orange Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
Wilmington
dei Entity Address State Or Province
EntityAddressStateOrProvince
DE
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19801
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
254-6134
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
67641314
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24548000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27605000
CY2021Q4 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
469000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
4582000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
19000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
292000
CY2021Q4 nrxp Notes Payable And Accrued Interest Current
NotesPayableAndAccruedInterestCurrent
518000
CY2022Q2 us-gaap Liabilities
Liabilities
7081000
CY2021Q4 us-gaap Liabilities
Liabilities
11923000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Assets
Assets
32729000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3078000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3687000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3326000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2375000
CY2022Q2 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
658000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7866000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5109000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
32414000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
32714000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2022Q2 us-gaap Assets
Assets
32433000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66641314
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58810550
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
67000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
59000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
228958000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
203990000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-203673000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183243000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
25352000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20806000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32433000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32729000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2958000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4659000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8441000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7568000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6642000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12458000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16864000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14558000
nrxp Settlement Expense
SettlementExpense
21366000
nrxp Expense Reimbursement
ExpenseReimbursement
771000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
9600000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
17117000
us-gaap Operating Expenses
OperatingExpenses
25305000
us-gaap Operating Expenses
OperatingExpenses
42721000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9600000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17117000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25305000
us-gaap Operating Income Loss
OperatingIncomeLoss
-42721000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
121000
CY2022Q2 us-gaap Interest Income Other
InterestIncomeOther
23000
us-gaap Interest Income Other
InterestIncomeOther
23000
CY2021Q2 us-gaap Interest Expense
InterestExpense
5000
us-gaap Interest Expense
InterestExpense
3000
us-gaap Interest Expense
InterestExpense
10000
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
116000
CY2021Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
17359000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
273000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
17359000
CY2022Q2 nrxp Gain Loss On Fair Value Of Cash Earn Out Liability
GainLossOnFairValueOfCashEarnOutLiability
2479000
CY2021Q2 nrxp Gain Loss On Fair Value Of Cash Earn Out Liability
GainLossOnFairValueOfCashEarnOutLiability
-355000
nrxp Gain Loss On Fair Value Of Cash Earn Out Liability
GainLossOnFairValueOfCashEarnOutLiability
4582000
nrxp Gain Loss On Fair Value Of Cash Earn Out Liability
GainLossOnFairValueOfCashEarnOutLiability
-355000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2618000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
16999000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4875000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
17115000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6982000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-118000
us-gaap Net Income Loss
NetIncomeLoss
-20430000
us-gaap Net Income Loss
NetIncomeLoss
-25606000
CY2021Q2 nrxp Deemed Dividend Warrants
DeemedDividendWarrants
255822000
nrxp Deemed Dividend Warrants
DeemedDividendWarrants
255822000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6982000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-255940000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20430000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-281428000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.11
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.13
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.32
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-7.27
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.11
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.43
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.32
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-7.63
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65732343
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41727480
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64348966
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38709614
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65732343
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42494386
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64348966
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39140261
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20806000
CY2022Q1 nrxp Sale Of Stock And Warrants Issuance Costs
SaleOfStockAndWarrantsIssuanceCosts
2020000
CY2022Q1 nrxp Common Stock And Warrants Issued In Private Placement Net Of Issuance Costs
CommonStockAndWarrantsIssuedInPrivatePlacementNetOfIssuanceCosts
22980000
CY2022Q1 nrxp Stock Issued For Payment Of Consulting Services
StockIssuedForPaymentOfConsultingServices
17000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1334000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13448000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
31689000
CY2022Q2 nrxp Private Placement Issuance Costs
PrivatePlacementIssuanceCosts
342000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
987000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6982000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
25352000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-43771000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6927000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7500000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
60852000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
372000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-25489000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
6391000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1562000
CY2021Q2 nrxp Net Of Redemptions And Issuance Costs
NetOfRedemptionsAndIssuanceCosts
1413000
CY2021Q2 nrxp Stock Repurchased During Period Value Merger And Recapitalization Net Of Redemptions And Issuance Costs
StockRepurchasedDuringPeriodValueMergerAndRecapitalizationNetOfRedemptionsAndIssuanceCosts
64836000
CY2021Q2 nrxp Financing Net Of Issuance Costs
FinancingNetOfIssuanceCosts
1900000
CY2021Q2 nrxp Stock Issued During Period Value New Issues From Private Investment In Equity
StockIssuedDuringPeriodValueNewIssuesFromPrivateInvestmentInEquity
8100000
CY2021Q2 nrxp Stock Issued For Payment Of Consulting Services
StockIssuedForPaymentOfConsultingServices
4850000
CY2021Q2 nrxp Adjustments To Additional Paid In Capital Modifications Of Stock Options Due To Business Combination
AdjustmentsToAdditionalPaidInCapitalModificationsOfStockOptionsDueToBusinessCombination
1014000
CY2021Q2 nrxp Adjustments To Additional Paid In Capital Modifications Of Warrant Issued Due To Business Combination
AdjustmentsToAdditionalPaidInCapitalModificationsOfWarrantIssuedDueToBusinessCombination
2331000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
938000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-39767000
us-gaap Net Income Loss
NetIncomeLoss
-20430000
us-gaap Net Income Loss
NetIncomeLoss
-25606000
us-gaap Depreciation
Depreciation
2000
us-gaap Depreciation
Depreciation
1000
us-gaap Share Based Compensation
ShareBasedCompensation
2321000
us-gaap Share Based Compensation
ShareBasedCompensation
4655000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
121000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-273000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-17359000
nrxp Gain Loss On Fair Value Of Cash Earnout Liability
GainLossOnFairValueOfCashEarnoutLiability
4582000
nrxp Gain Loss On Fair Value Of Cash Earnout Liability
GainLossOnFairValueOfCashEarnoutLiability
-355000
us-gaap Paid In Kind Interest
PaidInKindInterest
10000
nrxp Noncash Settlement Expense
NoncashSettlementExpense
21366000
nrxp Non Cash Consulting Expense
NonCashConsultingExpense
4850000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-831000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2757000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4849000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-609000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2563000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1157000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1105000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25171000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14409000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
6000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
3000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8489000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7500000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
11050000
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-518000
nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
22638000
nrxp Proceeds From Repayments Of Notes Payable Assumed In Merger
ProceedsFromRepaymentsOfNotesPayableAssumedInMerger
-1100000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22120000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25939000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3057000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
11527000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27605000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1859000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24548000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13386000
nrxp Reclassification Of Settlement Liability Upon Issuance Of Warrant
ReclassificationOfSettlementLiabilityUponIssuanceOfWarrant
60852000
nrxp Reclassification Of Legacy Warrants To Warrant Liability
ReclassificationOfLegacyWarrantsToWarrantLiability
38220000
nrxp Issuance Of Common Stock Warrants As Offering Costs
IssuanceOfCommonStockWarrantsAsOfferingCosts
726000
nrxp Extinguishment Of Paycheck Protection Program Loan
ExtinguishmentOfPaycheckProtectionProgramLoan
121000
us-gaap Stock Issued1
StockIssued1
17000
CY2021Q2 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-17477000
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-42965000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-255940000
CY2021Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
17359000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
17359000
CY2022Q2 us-gaap Cash
Cash
24500000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the Earnout Cash liability, valuation of common and preferred stock, stock options, warrants, and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk and Off-Balance Sheet Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. </p>
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-273299000
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.13
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-7.27
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.43
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-7.63
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-118000
us-gaap Net Income Loss
NetIncomeLoss
-25606000
CY2021Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
17359000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
17359000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-298788000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41727480
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38709614
CY2021Q2 nrxp Weighted Average Shares Outstanding Diluted Adjustment Reclassification Of Warrants Under Treasury Stock Method
WeightedAverageSharesOutstandingDilutedAdjustmentReclassificationOfWarrantsUnderTreasuryStockMethod
766906
nrxp Weighted Average Shares Outstanding Diluted Adjustment Reclassification Of Warrants Under Treasury Stock Method
WeightedAverageSharesOutstandingDilutedAdjustmentReclassificationOfWarrantsUnderTreasuryStockMethod
430647
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42494386
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39140261
nrxp Option Exchange Ratio Shares Earnout Shares For Common Stockholders
OptionExchangeRatioSharesEarnoutSharesForCommonStockholders
22209280
nrxp Option Exchange Ratio Value Earnout Cash For Common Stockholders
OptionExchangeRatioValueEarnoutCashForCommonStockholders
88800000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
456000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
180000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
743000
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
6523000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
3224000
CY2022Q2 nrxp Receivables Due From Manufacturers
ReceivablesDueFromManufacturers
554000
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
434000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
345000
CY2022Q2 nrxp Prepaid Legal Expenses
PrepaidLegalExpenses
255000
CY2022Q2 nrxp Prepaid Clinical Development Expenses
PrepaidClinicalDevelopmentExpenses
100000
CY2021Q4 nrxp Prepaid Clinical Development Expenses
PrepaidClinicalDevelopmentExpenses
512000
CY2021Q4 nrxp Prepaid Manufacturing Expenses Current
PrepaidManufacturingExpensesCurrent
1028000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7866000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5109000
CY2022Q2 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
300000
CY2021Q4 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1055000
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
288000
CY2022Q2 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
2558000
CY2021Q4 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
121000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3326000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2375000
CY2022Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2021Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 nrxp Common Stock And Warrants Issued In Private Placement Number Of Shares
CommonStockAndWarrantsIssuedInPrivatePlacementNumberOfShares
65526
CY2021Q2 nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
1400000
nrxp Common Stock And Warrants Issued In Private Placement Number Of Shares
CommonStockAndWarrantsIssuedInPrivatePlacementNumberOfShares
7824727
nrxp Common Stock And Warrants Issued In Private Placement Number Of Shares
CommonStockAndWarrantsIssuedInPrivatePlacementNumberOfShares
1894863
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9305790
CY2021 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P3Y11M1D
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.09
CY2021Q4 nrxp Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
4942000
nrxp Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
8215963
nrxp Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
P5Y6M
nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
3.11
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
17521753
nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P4Y14D
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.29
CY2022Q2 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted
P10Y
CY2022Q2 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.16
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.37
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
28500000
CY2022Q2 nrxp Allocated Share Based Compensation Expense Expected To Be Recognized In Future
AllocatedShareBasedCompensationExpenseExpectedToBeRecognizedInFuture
4000000.0
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
987000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4283000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2321000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4655000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
100000
CY2021Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
100000

Files In Submission

Name View Source Status
0001558370-22-013673-index-headers.html Edgar Link pending
0001558370-22-013673-index.html Edgar Link pending
0001558370-22-013673.txt Edgar Link pending
0001558370-22-013673-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrxp-20220630.xsd Edgar Link pending
nrxp-20220630x10q.htm Edgar Link pending
nrxp-20220630xex10d1.htm Edgar Link pending
nrxp-20220630xex10d1001.jpg Edgar Link pending
nrxp-20220630xex10d1002.jpg Edgar Link pending
nrxp-20220630xex31d1.htm Edgar Link pending
nrxp-20220630xex31d2.htm Edgar Link pending
nrxp-20220630xex32d1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nrxp-20220630x10q_htm.xml Edgar Link completed
nrxp-20220630xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
nrxp-20220630_def.xml Edgar Link unprocessable
nrxp-20220630_lab.xml Edgar Link unprocessable
nrxp-20220630_pre.xml Edgar Link unprocessable
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nrxp-20220630_cal.xml Edgar Link unprocessable